Fibroblast subtypes in pancreatic cancer and pancreatitis: from mechanisms to therapeutic strategies
Cellular Oncology · 2024
DOI: 10.1007/s13402-023-00874-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cellular Oncology, 2024. Verfasst von Huizhen Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shanghai Key Laboratory of Pancreatic Diseases, Shanghai General Hospital, Nanjing Medical University, Shanghai, Chin…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Fibroblasts. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding, CAMS Innovation Fund for Medical Science.
Abstract (Originalsprache)
Excessive fibrosis is a predominant feature of pancreatic stroma and plays a crucial role in the development and progression of pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP). Emerging evidence showed diversity and heterogeneity of fibroblasts play crucial and somewhat contradictory roles, the interactions between fibroblasts and pancreatic cells or infiltrating immune cells are of great importance during PDAC and CP progression, with some promising therapeutic strategies being tested. Therefore, in this review, we describe the classification of fibroblasts and their functions in PDAC and pancreatitis, the mechanisms by which fibroblasts mediate the development and progression of PDAC and CP through direct or indirect interaction between fibroblast and pancreatic parenchymal cells, or by remodeling the pancreatic immune microenvironment mediates the development and progression of PDAC and CP. Finally, we summarized the current therapeutic strategies and agents that directly target subtypes of fibroblasts or interfere with their essential functions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Shanghai Key Laboratory of Pancreatic Diseases, Shanghai General Hospital, Nanjing Medical University, Shanghai, China.
- Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine (PUMCH), Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Pek…
- State Key Laboratory of Complex, Severe, and Rare Diseases, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
- Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. f.cao@xwhosp.org.
- State Key Laboratory of Complex, Severe, and Rare Diseases, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China. wenli…
Förderung
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
- CAMS Innovation Fund for Medical Science
- Shanghai Natural Science Foundation
Zitieren
APA
Huang, H., Lu, W., Zhang, X., Pan, J., Cao, F., & Wen, L. (2024). Fibroblast subtypes in pancreatic cancer and pancreatitis: from mechanisms to therapeutic strategies. Cellular Oncology. https://doi.org/10.1007/s13402-023-00874-x
Vancouver
Huang H, Lu W, Zhang X, Pan J, Cao F, Wen L. Fibroblast subtypes in pancreatic cancer and pancreatitis: from mechanisms to therapeutic strategies. Cellular Oncology. 2024. doi:10.1007/s13402-023-00874-x
BibTeX
@article{Huang2024,
author = {Huang, Huizhen and Lu, Wanyi and Zhang, Xiuli and Pan, Jiachun and Cao, Feng and Wen, Li},
title = {Fibroblast subtypes in pancreatic cancer and pancreatitis: from mechanisms to therapeutic strategies},
journal = {Cellular Oncology},
year = {2024},
doi = {10.1007/s13402-023-00874-x}
}
EUVIMED